SkinBioTherapeutics’ Initial Public Offering

DAC Beachcroft advised nominated adviser, Cairn Financial Advisers LLP, and broker, Turner Pope Investments (TPI) Ltd, on the imminent admission of life sciences company, SkinBioTherapeutics, to the AIM market of the London Stock Exchange.

UK-based SkinBioTherapeutics will use its admission to AIM to fund the growth of its technology platform, SkinBiotix, which it has developed to research skin-related applications for cosmetics and healthcare.

DAC Beachcroft’s team on the deal was led by Clive Garston (Picture) with support from Legal Director, Michelle Jones.

Involved fees earner: Clive Garston – DAC Beachcroft; Michelle Jones – DAC Beachcroft;

Law Firms: DAC Beachcroft;

Clients: Cairn Financial Advisers LLP; Turner Pope Investments Ltd;

Print Friendly, PDF & Email